Following the publication of this paper, the authors requested that Daqing Zhao also be included as a joint author for correspondence. The Editor has granted this request, and therefore, the revised information for the corresponding authors is presented as follows (changes highlighted in bold): MANYING WANG1,2*, RUI JIANG1*, JIANZENG LIU2, XIAOHAO XU1, GUANG SUN1, DAQING ZHAO2,3 and LIWEI SUWN1,3. 1Research Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin 130021; 2Jilin Ginseng Academy, Changchun University of Chinese Medicine; 3Key Laboratory of Active Substances and Biological Mechanisms of Ginseng Efficacy, Ministry of Education, Changchun, Jilin 130117, P.R. China. Correspondence to: Professor Liwei Sun, Research Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, 1478 Gongnong Street, Changchun, Jilin 130021, P.R. China. E‑mail: sunnylilwei@163.com. Professor Daqing Zhao, Jilin Ginseng Academy, Changchun University of Chinese Medicine, 1035 Boshuo Road, Changchun, Jilin 130117, P.R. China. E‑mail: zhaodaqing1963@163.com. All the authors agree to this Corrigendum, and they are grateful to the Editor for allowing this Corrigendum to be published. [the original article was published in Molecular Medicine Reports 23: Article no. 306, 2021; DOI: 10.3892/mmr.2021.11945].
Keywords: 20(S)‑ginsenoside Rg3; AMP‑activated protein kinase/forkheadbox O3; mitochondrial dysfunction; skeletal muscle atrophy.